Profile data is unavailable for this security.
About the company
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
- Revenue in USD (TTM)0.00
- Net income in USD-94.30m
- Incorporated2012
- Employees20.00
- LocationRelmada Therapeutics Inc2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES 33134United StatesUSA
- Phone+1 (646) 876-3459
- Websitehttps://www.relmada.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gritstone bio Inc | 15.65m | -144.89m | 89.28m | 231.00 | -- | 5.78 | -- | 5.71 | -1.57 | -1.57 | 0.17 | 0.1423 | 0.0901 | -- | 40.53 | 67,727.27 | -83.47 | -48.08 | -97.70 | -55.18 | -- | -- | -926.13 | -573.71 | -- | -554.88 | 0.7428 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
Precision BioSciences Inc | 57.53m | -19.99m | 90.03m | 109.00 | -- | 2.42 | -- | 1.56 | -5.50 | -7.41 | 13.76 | 5.38 | 0.2956 | -- | 47.10 | 527,807.30 | -10.27 | -35.35 | -12.94 | -44.22 | -- | -- | -34.74 | -147.50 | -- | -- | 0.3764 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
Angion Biomedica Corp | 0.00 | -38.99m | 90.55m | 32.00 | -- | 18.57 | -- | -- | -6.63 | -6.63 | 0.00 | 0.4765 | 0.00 | -- | -- | 0.00 | -117.72 | -105.91 | -133.85 | -331.69 | -- | -- | -- | -712.81 | -- | -- | 0.00 | -- | -100.00 | -- | 9.31 | -- | -- | -- |
Eton Pharmaceuticals Inc | 34.30m | 913.00k | 92.49m | 30.00 | 106.41 | 5.97 | 49.91 | 2.70 | 0.0338 | 0.0338 | 1.33 | 0.6031 | 1.25 | 8.41 | 9.64 | 1,143,467.00 | 3.34 | -46.22 | 5.72 | -58.20 | 66.24 | 72.16 | 2.66 | -76.86 | 1.43 | -- | 0.2447 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 92.64m | 35.00 | 410.98 | 365.90 | -- | 37.15 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
Milestone Pharmaceuticals Inc | 0.00 | -55.09m | 93.21m | 47.00 | -- | 2.33 | -- | -- | -1.25 | -1.25 | 0.00 | 0.7498 | 0.00 | -- | -- | 0.00 | -53.21 | -48.44 | -56.51 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.5592 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
LifeVantage Corp | 205.45m | 3.60m | 93.48m | 248.00 | 26.33 | 3.49 | 12.85 | 0.455 | 0.2796 | 0.2796 | 16.01 | 2.11 | 3.20 | 2.53 | 91.56 | 828,443.60 | 5.60 | 11.65 | 8.51 | 18.92 | 79.32 | 82.20 | 1.75 | 3.42 | 1.01 | -- | 0.00 | 5.23 | 3.41 | 0.9838 | -18.59 | -18.77 | -7.98 | -- |
Relmada Therapeutics Inc | 0.00 | -94.30m | 93.84m | 20.00 | -- | 1.30 | -- | -- | -3.13 | -3.13 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -85.74 | -- | -95.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
Nanopharmaceutics Inc | 1.01m | -549.47k | 93.95m | 50.00 | -- | -- | -- | 93.06 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
Armata Pharmaceuticals Inc | 4.70m | -79.58m | 94.00m | 66.00 | -- | -- | -- | 20.00 | -2.20 | -2.20 | 0.1302 | -1.56 | 0.041 | -- | 3.16 | 71,196.97 | -69.46 | -59.78 | -235.17 | -72.70 | -- | -- | -1,693.47 | -1,113.72 | -- | -1.11 | 1.75 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
Oramed Pharmaceuticals, Inc. | 674.00k | 10.46m | 94.26m | 15.00 | 9.33 | 0.5641 | 9.02 | 139.85 | 0.2488 | 0.2488 | 0.0165 | 4.11 | 0.0037 | -- | -- | 44,933.33 | 5.63 | -- | 6.27 | -- | -- | -- | 1,518.25 | -- | -- | -- | 0.162 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
Leap Therapeutics Inc | 0.00 | -53.37m | 94.51m | 54.00 | -- | 1.33 | -- | -- | -2.39 | -2.39 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -64.88 | -80.06 | -74.25 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
Assertio Holdings Inc | 142.05m | -332.97m | 96.08m | 53.00 | -- | 0.7143 | -- | 0.6764 | -3.95 | -3.95 | 1.66 | 1.41 | 0.4081 | 1.19 | 3.19 | 2,680,208.00 | -95.65 | -21.51 | -130.77 | -32.05 | 76.96 | 88.68 | -234.40 | -62.10 | 1.45 | -- | 0.2231 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
Athira Pharma Inc | 0.00 | -116.19m | 98.12m | 65.00 | -- | 0.9192 | -- | -- | -3.05 | -3.05 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -63.45 | -30.73 | -72.51 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
Connect Biopharma Holdings Ltd (ADR) | 0.00 | -59.50m | 99.19m | 81.00 | -- | 1.02 | -- | -- | -1.08 | -1.08 | 0.00 | 1.76 | -- | -- | -- | 0.00 | -- | -66.24 | -- | -71.36 | -- | -- | -- | -- | -- | -- | 0.0046 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.25m | 4.13% |
Deep Track Capital LPas of 31 Mar 2024 | 1.24m | 4.11% |
Vestal Point Capital LPas of 31 Mar 2024 | 1.20m | 3.98% |
Acadian Asset Management LLCas of 31 Mar 2024 | 1.18m | 3.92% |
Parsons Capital Management, Inc.as of 31 Mar 2024 | 973.52k | 3.23% |
Opaleye Management, Inc.as of 31 Mar 2024 | 759.00k | 2.52% |
Palo Alto Investors LPas of 31 Mar 2024 | 732.40k | 2.43% |
Franklin Advisers, Inc.as of 31 Mar 2024 | 630.25k | 2.09% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 567.32k | 1.88% |
Millennium Management LLCas of 31 Mar 2024 | 341.45k | 1.13% |